Combined inhibition of TLR4 and SPHK1 synergizes with TMZ to suppress tumor growth and reverse M2 macrophage polarization in vivo, highlighting the therapeutic promise of targeting the ENO1/TLR4-SPHK1 axis. Here, ENO1 is linked to neoplasm.